PDUFA dates August 2019: FDA calendar and catalysts.
0 PDUFA dates fell in August 2019. The FDA calendar also recorded 10 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in August 2019
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
August 2019: other FDA decisions and filings
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| August 6, 2019 | Epzicom (abacavir sulfate; lamivudine) | VTRS | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| August 7, 2019 | Eysuvis (loteprednol etabonate) | KALA | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| August 14, 2019 | WAKIX® (pitolisant) | HRMY | FDA approval | — | Approved | openFDA Drugs@FDA |
| August 14, 2019 | Pretomanid (pretomanid) | VTRS | FDA approval | — | Approved | openFDA Drugs@FDA |
| August 16, 2019 | RINVOQ® (upadacitinib) | ABBV | FDA approval | — | Approved | openFDA Drugs@FDA |
| August 16, 2019 | Inrebic (fedratinib hydrochloride) | BMY | FDA approval | — | Approved | openFDA Drugs@FDA |
| August 19, 2019 | Vyondys 53 (golodirsen) | SRPT | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| August 28, 2019 | Harvoni (ledipasvir; sofosbuvir) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| August 28, 2019 | Sovaldi® (sofosbuvir) | GILD | FDA approval | — | Approved | openFDA Drugs@FDA |
| August 28, 2019 | nda210605 | VTRS | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
August 2019: dated readouts
No events in this view.
Questions
What PDUFA dates are in August 2019?
0 PDUFA dates fell in August 2019. The FDA calendar also recorded 10 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.